<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6(5)</volume><submitter>Xu L</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>CD4(+)CD25(+) regulatory T cells (Tregs), a heterogeneous population, were enrichment in tumor mass and played an important role in modulating anti-tumor immunity. Recently, we reported a Treg subset, CCR6(+) Tregs but not CCR6(-)Tregs, were enriched in tumor mass and closely related to poor prognosis of breast cancer patients. However, the underlying mechanism remains elusive. Here, we carefully evaluate the enrichment of CCR6(+)Tregs in tumor mass during progression of breast cancer and explore its possible mechanism.&lt;h4>Methodology/principal findings&lt;/h4>The frequency of CCR6(+)Tregs in tumor infiltrating lymphocytes (TILs ) was analyzed at early stage and at late stage of tumor in a murine breast cancer model by FACS respectively. The expansion of CCR6(+)Tregs and th</pubmed_abstract><journal>PloS one</journal><pagination>e20282</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3105045</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>In situ prior proliferation of CD4+ CCR6+ regulatory T cells facilitated by TGF-β secreting DCs is crucial for their enrichment and suppression in tumor immunity.</pubmed_title><pmcid>PMC3105045</pmcid><pubmed_authors>Xu L</pubmed_authors><pubmed_authors>Wen Z</pubmed_authors><pubmed_authors>Xiong S</pubmed_authors><pubmed_authors>Xu W</pubmed_authors></additional><is_claimable>false</is_claimable><name>In situ prior proliferation of CD4+ CCR6+ regulatory T cells facilitated by TGF-β secreting DCs is crucial for their enrichment and suppression in tumor immunity.</name><description>&lt;h4>Background&lt;/h4>CD4(+)CD25(+) regulatory T cells (Tregs), a heterogeneous population, were enrichment in tumor mass and played an important role in modulating anti-tumor immunity. Recently, we reported a Treg subset, CCR6(+) Tregs but not CCR6(-)Tregs, were enriched in tumor mass and closely related to poor prognosis of breast cancer patients. However, the underlying mechanism remains elusive. Here, we carefully evaluate the enrichment of CCR6(+)Tregs in tumor mass during progression of breast cancer and explore its possible mechanism.&lt;h4>Methodology/principal findings&lt;/h4>The frequency of CCR6(+)Tregs in tumor infiltrating lymphocytes (TILs ) was analyzed at early stage and at late stage of tumor in a murine breast cancer model by FACS respectively. The expansion of CCR6(+)Tregs and th</description><dates><release>2011-01-01T00:00:00Z</release><publication>2011</publication><modification>2025-07-08T03:12:45.243Z</modification><creation>2025-07-08T03:12:45.243Z</creation></dates><accession>S-EPMC3105045</accession><cross_references><pubmed>21655250</pubmed><doi>10.1371/journal.pone.0020282</doi></cross_references></HashMap>